A pricey new Alzheimer’s drug already mired in controversy could cost Medicaid anywhere from $720 million to nearly $2.2 billion each year depending on the number of patients treated, according to a new analysis.
The medication, which is called Aduhelm and carries a $56,000 price tag, is generating concern over its potential impact on the overall health care system. The Centers for Medicare & Medicaid Services, for instance, is about to begin a process for determining whether Medicare will establish a national coverage policy for the drug, which is sold by Biogen (BIIB) and won regulatory approval last month.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
